Literature DB >> 9566474

Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716.

G Colombo1, R Agabio, M Fà, L Guano, C Lobina, A Loche, R Reali, G L Gessa.   

Abstract

The present study assessed the efficacy of the cannabinoid CB1 receptor antagonist, SR-141716, in reducing voluntary ethanol intake in selectively bred Sardinian alcohol-preferring (sP) rats. Ethanol (10%, v/v) and food were available in daily 4 h scheduled access periods; water was present 24 h/day. The acute administration of a 2.5 and a 5 mg/kg dose of SR-141716 selectively reduced ethanol intake, whereas a 10 mg/kg dose of SR-141716 reduced to a similar extent both ethanol and food intake. These results suggest that the cannabinoid CB1 receptor is involved in the mediation of the ethanol-reinforcing effects in sP rats.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9566474     DOI： 10.1093/oxfordjournals.alcalc.a008368

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN： 0735-0414            Impact factor:   2.826


  60 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.

Authors:  Jason E Gallate; Paul E Mallet; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

4.  Is cannabinoid transmission involved in rewarding properties of drugs of abuse?

Authors:  Daniela Parolaro; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.

Authors:  J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

Review 6.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

7.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

8.  Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex.

Authors:  Veronica C Oropeza; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

9.  Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.

Authors:  Lei Wang; Jie Liu; Judith Harvey-White; Andreas Zimmer; George Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

10.  Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers.

Authors:  David Ted George; David W Herion; Cheryl L Jones; Monte J Phillips; Jacqueline Hersh; Debra Hill; Markus Heilig; Vijay A Ramchandani; Christopher Geyer; David E Spero; Erick D Singley; Stephanie S O'Malley; Raafat Bishai; Robert R Rawlings; George Kunos
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.